Physician profile
Mark Kats
NPI 1215140355
$758.37
in general payments reported to CMS, 2019-2025
18 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.62 · 2021: $48.28 · 2022: $231 · 2023: $44.65 · 2024: $129 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Education: $49.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.97 |
| Education | $49.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $109.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $94.60 | 2021-2023 | Jynarque |
| Vifor Pharma, INC. | $72.98 | 2022-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $72.87 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $47.94 | 2024-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $45.73 | 2025 | |
| Travere Therapeutics, INC. | $42.76 | 2020-2025 | |
| Novo Nordisk INC | $36.44 | 2024-2025 | Ozempic, Rybelsus |
| Baxter Healthcare | $33.93 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Aurinia Pharma U.S., INC. | $28.91 | 2025 | Lupkynis |
| Electromed, INC. | $25.49 | 2025 | Smartvest |
| Opko Pharmaceuticals, LLC | $25.36 | 2025 | Rayaldee |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Ardelyx, INC. | $22.10 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $21.77 | 2024 | Velphoro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $19.99 | 2025 | Purified Cortrophin Gel |
| Embecta Corp. | $17.54 | 2024 | |
| Lilly USA, LLC | $15.82 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.